Silexion Reports SIL204 Uses Native Lipoproteins for Cellular Uptake, Supports Systemic Phase 2/3 Plan
Silexion reports positive preclinical data showing SIL204 leverages endogenous serum lipids for dose-dependent KRAS knockdown.Key Highlights:Original SEC Filing: Silexion Therapeutics Corp [ SLXN ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying i…